Some Factors Influencing Distribution, Metabolism and Action of Barbiturates

Richards, R. K.; Taylor, J D

doi:10.1097/00000542-195605000-00005

Cited by 51 publications

(14 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Corresponding studies in man have not been described in the main reviews of barbiturate metabolism (Bush & Sanders, 1967;Mark, 1963;Raventos, 1954;Richards & Taylor, 1956). Kamm & van Loon (1966) did not compare hydroxyamylobarbitone excretion rates in men and women.…”

Section: Introductionmentioning

confidence: 99%

The kinetics of amylobarbitone metabolism in healthy men and women

Balasubramaniam

Lucas

Mawer

et al. 1970

British J Pharmacology

View full text Add to dashboard Cite

Sodium amylobarbitone (3·54 mg/kg) was given by intravenous injection to seven healthy men and nine healthy women who were not receiving other drugs. Serum amylobarbitone and urine hydroxyamylobarbitone concentrations were measured by gas‐liquid chromatography. There was no significant difference between the groups either in the serum amylobarbitone concentration/time curves or in the urinary excretion of hydroxyamylobarbitone. The serum amylobarbitone concentration decayed over 48 h as a double exponential function of time; the first exponential component had a mean half‐time of 0·6 h (males 0·56 ± 0·06 h, females 0·62 ± 0·08 h, ± s.e.) and the second exponential component had a mean half time of 21 h (males 22·7 ± 1·6 h, females 20·0 ± 1·0 h, ± s.e.). The urinary excretion of hydroxyamylobarbitone over 48 h accounted for 34% of the dose (males 33·8 ± 3·2%, females 35·2 ± 3·0%, ± s.e.). One male and two female subjects excreted hydroxyamylobarbitone partly as a conjugate which was readily hydrolysed in acid. An elimination constant (kel) derived from the serum concentration/time curve by the application of a two compartment model was approximately proportional to β (h−1), the rate constant of the second exponential component. There was a positive correlation (r=0·78, P<0·001) between β and the mean rate of urinary excretion of hydroxyamylobarbitone during the 24 to 48 h period.

show abstract

Section: Introductionmentioning

confidence: 99%

The kinetics of amylobarbitone metabolism in healthy men and women

Balasubramaniam

Lucas

Mawer

et al. 1970

British J Pharmacology

View full text Add to dashboard Cite

show abstract

“…One may consider as a logical explanation the influence of a phenomenon of redistribution of the drug in adipose tissues, This phenomenon, described first in the case of pentobarbitone (Brodie, Bernstein & Mark 1952), is also known for other barbiturates (Richards & Taylor 1956).…”

Section: Discussionmentioning

confidence: 99%

Study of urinary excretion of butobarbitone in man in relation to the percentage of ideal body weight.

Cheymol¹,

Bernheim²,

Besson³

et al. 1979

Brit J Clinical Pharma

View full text Add to dashboard Cite

I Thirty-three patients with no evidence of endocrine disease, hepatic or renal insufficiency or sleep disorders, were classified in groups 1 to 4 in order of increasing of percentage of ideal body weight (IBW) respectively: < 90% of IBW, 90-120%, 120-180%, and > 180% of IBW. After oral administration of 200 mg butobarbitone, concentration of the intact drug was measured by gas liquid chromatographic assay in urine samples collected during 72 h and at three times in blood. 2 A highly significant negative relationship was found between the cumulative excretion of butobarbitone with urine and the logarithm of the percentage of IBW. In contrast for a given weight, excretion of the drug with urine was found to be weakly correlated with the diuresis. 3 The cumulative urinary elimination of butobarbitone was significantly different between the groups studied, except of the difference between the group 2 and 3 of the patients. No significant difference was found between the renal clearances ofbutobarbitone in the four groups of subjects. 4 We conclude that redistribution of butobarbitone into adipose tissues can explain the obtained results and that obesity modifies the pharmacokinetics of the drug.

show abstract

“…Es muß nach unse ren Ergebnissen durchaus damit gerechnet werden, daß eine in einer solchen Anordnung beobachtete signifikante Schlafzeitver längerung die Folge einer unspezifischen Wasserüberladung des Organismus ist und mit der Vorbehandlung unter Umständen nur in einem sehr losen Zusammenhang steht. Für diese Auffassung spricht der Befund, daß sich solche am kleinen Tier erhal tenen Befunde oftmals an größeren Tieren, denen relativ viel weniger Flüssigkeit appliziert wird, nicht reproduzieren lassen (Übersicht bei Richards and Taylor, 1956). Auf die Bedeutung des Wasserhaushaltes für die Narkosedauer beim kleinen Ver suchstier haben u. a. die Untersuchungen von Kaufmann (1955) und Ramwell andLester (1961) …”

Section: Methodikunclassified

Toleranz kleiner Laboratoriumstiere gegenüber intravenös injizierten Flüssigkeitsmengen und Einfluß des Injektionsvolumens auf einige Arzneimittelwirkungen

Kampmann¹,

Frey²

1963

Pharmacology

View full text Add to dashboard Cite

Some Factors Influencing Distribution, Metabolism and Action of Barbiturates

Cited by 51 publications

References 0 publications

The kinetics of amylobarbitone metabolism in healthy men and women

The kinetics of amylobarbitone metabolism in healthy men and women

Study of urinary excretion of butobarbitone in man in relation to the percentage of ideal body weight.

Toleranz kleiner Laboratoriumstiere gegenüber intravenös injizierten Flüssigkeitsmengen und Einfluß des Injektionsvolumens auf einige Arzneimittelwirkungen

Contact Info

Product

Resources

About